natgillin/translations-raw huggingface dataset:
- Infection: if you experience signs of infection caused by bacteria or virus, or other organisms.
- Okužba: če imate znake okužbe, ki jo povzroči bakterija ali virus ali drugi organizmi.
but there was no evidence of teratogenicity.
Dokazov o teratogenosti ni bilo.
Body Surface Area (m
Telesna površina (m
The median follow up at the time of the analysis was 6.9 years.
Mediana spremljanja v času analize je bila 6,9 leta.
Careful monitoring during the first cycle of treatment is recommended for all patients.
Skrbno spremljanje med prvim ciklom zdravljenja je priporočljivo za vse bolnike.
This is calculated from your height and weight.
Ta se izračuna iz vaše višine in telesne mase.
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve glede predložitve PSUR za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Therefore, in the absence of serious toxicity the dose could be increased while carefully monitoring the patient.
Zato je v odsotnosti resne toksičnosti odmerek mogoče povečati in bolnika pozorno spremljati.
The AUC of 5-FU was 30%-35% higher on day 14.
AUC 5-FU je bila od 30 do 35 % višja štirinajstega dne.
These findings are expected effects of fluoropyrimidine derivatives.
Te ugotovitve so posledica učinkov derivatov fluoropirimidina.
• Periodic safety update reports (PSURs)
• Redno posodobljena poročila o varnosti zdravila (PSUR)
Once the dose has been reduced, it should not be increased at a later time.
Ko je odmerek zmanjšan, ga pozneje ne smemo več zvečati.
Ecansya tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken).
Tablete zdravila Ecansya se običajno jemljejo 14 dni, čemur sledi 7-dnevni premor (ko se tablet ne jemlje).
Interrupt until resolved to grade 0-1
1. pojav prekinitev, dokler ni dosežena stopnja 0−1
See also section "Do not take Ecansya".
Glejte tudi poglavje "Ne jemljite zdravila Ecansya".
It is not known whether capecitabine is excreted in human breast milk.
Ni znano, ali se kapecitabin izloča v človeško mleko.
Median overall survival ITT
Mediana celokupnega preživetja ITT
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov proizvajalca, odgovornega za sprostitev zadevne serije.
Ecansya tablets should not be crushed or cut.
Tablet zdravila Ecansya se ne sme drobiti ali rezati.
Hand and foot skin reaction can lead to loss of fingerprint, which could impact your identification by fingerprint scan.
Kožna reakcija na rokah in nogah lahko povzroči izgubo prstnih odtisov, kar bi lahko vplivalo na vašo identifikacijo s prstnimi odtisi.
Ecansya may be used either alone or in combination with other medicines.
Zdravilo Ecansya se lahko uporablja samostojno ali v kombinaciji z drugimi zdravili.
If you cannot swallow Ecansya tablets whole, tell your healthcare provider.
Če ne morete pogoltniti celih tablet zdravila Ecansya, obvestite zdravstvenega delavca.
FBAL is a metabolite without antiproliferative activity.
FBAL je presnovek brez antiproliferativnega učinka.
Your doctor will prescribe a dose and treatment regimen that is right for you.
Zdravnik vam bo predpisal odmerek in režim zdravljenja, ki bo namenjen le vam.
These reactions occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within one month after stopping capecitabine.
Ti učinki so se pojavili v nekaj dneh do celo nekaj mesecev po začetku zdravljenja s kapecitabinom, v nekaterih primerih celo čez en mesec po prenehanju zdravljenja s kapecitabinom.
- Take the tablets within 30 minutes after the end of a meal (breakfast and dinner) and swallow whole with water.
- Tablete zaužijte v 30 minutah po koncu obroka (zajtrka in večerje); tablete pogoltnite cele z vodo.
Food interaction
Interakcije s hrano
North Harrow, Middx HA1 4HF
North Harrow, Middx HA1 4HF Velika Britanija
The consequences of a reduced dose for efficacy are currently uncertain.
Trenutno ni znano, kakšne so posledice zmanjšanih odmerkov na učinkovitost.
Instead, continue your regular dosing schedule and check with your doctor.
Nadaljujte z rednim urnikom jemanja in se posvetujte z zdravnikom.
Do not take Ecansya - if you are allergic to capecitabine or any of the other ingredients of this medicine (listed in section 6).
Ne jemljite zdravila Ecansya - če ste alergični na kapecitabin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
See leaflet for further information.
Za nadaljnje informacije glejte navodilo za uporabo.
- If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used.
- Če obstajajo kontraindikacije za katero od zdravil, ki se uporablja v kombinaciji, se tega zdravila ne sme uporabljati.
ADDITIONAL 6 MONTHS OF FOLLOW UP
DODATNO ŠESTMESEČNO SPREMLJANJE
In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately.
V primeru akutne toksičnosti stopnje 2−4 je treba zdravljenje nemudoma prekiniti.
Ecansya has minor or moderate influence on the ability to drive and use machines.
Ecansya ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Dose reduction should be applied as necessary (see section 4.2).
Odmerek je treba zmanjšati, kot je to potrebno (glejte poglavje 4.2).
25.5 months
25,5 meseca
Most adverse reactions are reversible and do not require permanent discontinuation of therapy, although doses may need to be withheld or reduced.
Večina neželenih učinkov je reverzibilnih in ne zahteva dokončne prekinitve zdravljenja, vendar je včasih treba odmerjanje začasno prekiniti ali zmanjšati.
Reduced dose
Zmanjšani odmerek
The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL).
AUC za FBAL je z leti naraščala (20- % povečanje v letih daje 15- % povečanje AUC za FBAL).
All treatment cycles were administered at intervals of 3 weeks.
Vsi cikli zdravljenja so bili dani v intervalih po 3 tedne.
The dose of Ecansya is based on your body surface area.
Odmerek zdravila Ecansya je določen glede na vašo telesno površino.
Rare/Very Rare (Post-Marketing Experience)
Redki/zelo redki (izkušnje po prihodu zdravila na trg)
This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal.
To medsebojno delovanje, ki poveča toksičnost fluoropirimidina, je lahko smrtno.
In animal studies effects on fertility were observed (see section 5.3).
V študijah na živalih so ugotovili vpliv na plodnost (glejte poglavje 5.3).
The patients who are tested negative for the above-mentioned alleles may still have a risk of severe adverse events.
Bolniki z negativnimi testi na zgoraj omenjene alele imajo lahko kljub temu tveganje za hude neželene učinke.
Capecitabine is activated via several enzymatic steps (see section 5.2).
Kapecitabin se aktivira prek več encimov (glejte poglavje 5.2).
ADDITIONAL 1 YEAR OF FOLLOW UP
DODATNO ENOLETNO SPREMLJANJE
Other side effects are:
Drugi neželeni učinki so:
- difficulty in urination, blood or protein in the urine - bruising or reaction at the injection site (caused by medicines given by injection at the same time)
- težave pri uriniranju, kri ali beljakovine v urinu, - modrice ali reakcijo na mestu injiciranja (povzročeno z zdravili, ki se dajejo istočasno v obliki injekcije).
Data on the frequency of these DPYD variants in other populations than Caucasian is limited.
Podatkov o pogostnosti teh različic DPYD pri drugih populacijah razen belcev je malo.
Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumour tissue than in normal tissue).
Šele po absorpciji v telesu se spremeni v aktivno citostatično zdravilo (bolj v tumorskem tkivu kot v zdravih tkivih).
Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities.
O trajni ukinitvi zdravljenja je treba razmisliti glede na klinično oceno začetka, trajanja in resnosti opaženih toksičnosti.
Do not crush or cut tablets.
Tablet ne drobite in ne režite.
Day 1, prior to XELOX, every 3 weeks
1. dan, pred XELOX, vsake 3 tedne
Contact your doctor immediately if you are concerned about any of the side effects or if you notice any additional side effects not listed in the leaflet (see section 4 Possible side effects).
Nemudoma obvestite zdravnika, če vas skrbi kateri koli od neželenih učinkov ali če opazite kateri koli dodatni neželeni učinek, ki ni naveden v tem navodilu (glejte poglavje 4, Možni neželeni učinki).
If you have taken brivudine you must wait for at least 4 weeks after stopping brivudine before starting to take capecitabine.
Če ste jemali brivudin, morate po končanem jemanju brivudina počakati najmanj 4 tedne, preden začnete jemati kapecitabin.
Careful monitoring of patients 60 years of age is advisable.
Priporočljivo je skrbno spremljanje bolnikov, starih 60 let ali več.
The following are the recommended dose modifications for toxicity.
Sledijo priporočila za prilagajanje odmerkov pri toksičnosti.
Cytochrome P-450 2C9 substrates: Other than warfarin, no formal interaction studies between capecitabine and other CYP2C9 substrates have been conducted.
Substrati citokroma P-450 2C9: Razen z varfarinom, formalnih študij medsebojnega delovanja med kapecitabinom in drugimi substrati CYP2C9 niso izvedli.
Do not take a double dose to make up for a forgotten dose.
Ne vzemite dvojnega odmerka, da bi nadomestili izpuščeni odmerek.
For hand-foot syndrome and hyperbilirubinemia, see section 4.4.
Za sindrom roka--noga in hiperbilirubinemijo glejte poglavje 4.4.
Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Patients taking capecitabine should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs.
Bolniki, ki jemljejo kapecitabin, morajo biti obveščeni glede takojšnje prekinitve zdravljenja, če se pojavijo zmerne ali hude toksičnosti.
If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 10
Če laboratorijski izvid med ciklom zdravljenja pokaže, da se je število nevtrofilcev znižalo pod 1,0 x 10
Severe and/or Lifethreatening (grade 34) or considered medically relevant
Hudi in/ali življenjsko ogrožajoči (stopnja 3-4) ali klinično pomembni
Stevens-Johnson Syndrome and toxic Epidermal Necrolysis (very rare) (see section 4.4.)
Stevens- Johnsono v sindrom in toksična epidermalna nekroliza (zelo redki) (glejte poglavje 4.4)
Since metabolism of R-warfarin was not affected, these results indicate that capecitabine downregulates isozyme 2C9, but has no effect on isozymes 1A2 and 3A4.
Ker na presnovo R-varfarina ni bilo vpliva, ti rezultati nakazujejo, da kapecitabin zavira izoencim 2C9, ne vpliva pa na izoencima 1A2 in 3A4.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Your doctor may instruct you to restart treatment at a lower dose.
Morda vam bo predpisal nadaljevanje zdravljenja z manjšimi odmerki.
Persistent or severe hand-foot syndrome (Grade 2 and above) can eventually lead to loss of fingerprints which could impact patient identification.
Vztrajen ali hud sindrom roka-noga (2. stopnje ali višje) lahko sčasoma privede do izgube prstnih odtisov, kar lahko vpliva na identifikacijo bolnika.
24.4 months
24,4 meseca
Fatal cases have been reported following this drug interaction.
V povezavi s tem medsebojnim delovanjem so poročali o smrtnih primerih.
Previous therapy should have included an anthracycline.
Predhodno zdravljenje naj bi vključevalo antraciklin.
• Grade 1
• Stopnja 1
No dose has been proven safe for patients with complete absence of DPD activity.
Za bolnike s popolno odsotnostjo aktivnosti DPD ni varen noben odmerek.
Pharmacokinetics in special populations
Farmakokinetika pri posebnih skupinah
Ecansya should be permanently discontinued in patients who experience a severe skin reaction during treatment.
Zdravilo Ecansya je treba trajno ukiniti pri bolnikih, pri katerih se med zdravljenjem pojavi huda kožna reakcija.
Progression-free Survival after 6 months ITT
Preživetje brez napredovanja bolezni po 6 mesecih ITT
Each pack contains 30, 60 or 120 film-coated tablets.
Eno pakiranje vsebuje 30, 60 ali 120 filmsko obloženih tablet.
Day 1, prior to FOLFOX-4, every 2 weeks
1. dan, pred FOLFOX-4, vsake 2 tedna
The major metabolite excreted in urine is FBAL, which represents 57% of the administered dose.
Glavni presnovek, ki se izloča z urinom, je FBAL, katerega delež je 57 % zaužitega odmerka.
The inclusion of bevacizumab in a combination regimen has no effect on the starting dose of capecitabine.
Vključitev bevacizumaba v kombinacijo nima vpliva na začetni odmerek kapecitabina.
About 3% of the administered dose is excreted in urine unchanged.
Približno 3 % kapecitabina se izločijo nespremenjeni.
Severe skin reactions: Ecansya can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Hude kožne reakcije: Zdravilo Ecansya lahko izzove hude kožne reakcije, kot sta Stevens-Johnsonov sindrom in toksična epidermalna nekroliza.
Since DNA and RNA are essential for cell division and growth, the effect of 5-FU may be to create a thymidine deficiency that provokes unbalanced growth and death of a cell.
Ker sta RNA in DNA bistveni za rast in delitev celice, povzroči 5-FU pomanjkanje timidina, kar izzove neuravnoteženo rast in smrt celice.
5-Fluorouracil: intravenous bolus injection immediately after leucovorin
5- fluorouracil: intravenska injekcija v bolusu neposredno po levkovorinu
( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Neželeni učinki so razvrščeni po njihovi pogostnosti: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
Medical management of overdose should include customary therapeutic and supportive medical interventions aimed at correcting the presenting clinical manifestations and preventing their possible complications.
Zdravljenje prevelikega odmerjanja mora vključevati standardne terapevtske in podporne medicinske postopke, ki so namenjeni zdravljenju trenutnih kliničnih simptomov in preprečevanju nadaljnjih zapletov.
Treatment of eye disorders should be initiated as clinically appropriate.
Z njihovim zdravljenjem je treba pričeti, kot je klinično ustrezno.
Exposure to crushed or cut capecitabine tablets:
Izpostavljenost zdrobljenim ali razrezanim tabletam kapecitabina:
DPD deficiency: DPD deficiency is a rare condition present at birth that is not usually associated with health problems unless you receive certain medicines.
Pomanjkanje encima dihidropirimidin dehidrogenaze (DPD): Pomanjkanje encima DPD je redko prirojeno stanje, ki navadno ne povzroča težav z zdravjem, razen če prejmete določena zdravila.
Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer.
Nekateri od teh neželenih učinkov so bolj pogosti, če kapecitabin uporabljamo z drugimi zdravili za zdravljenje raka.
The parameters of capecitabine, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR) measured on days 1 and 14 were similar.
Parametri kapecitabina, 5'-deoksi-5-fluorocitidina (5'-DFCR) in 5'-deoksi-5-fluorouridina (5'-DFUR), ki so jih izmerili prvi in štirinajsti dan, so bili podobni.
The incorporation of 5-FU also leads to inhibition of RNA and protein synthesis.
Vgraditev 5-FU zavira tudi sintezo RNA in proteinov.
This may also be relevant with folic acid supplementation for folate deficiency due to the similarity between folinic acid and folic acid.
To je lahko pomembno tudi pri jemanju dodatkov s folno kislino pri pomanjkanju folatov zaradi podobnosti med folinsko in folno kislino.
If caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation.
Če ukrepamo takoj, neželeni učinki ponavadi minejo v 2 do 3 dneh po prekinitvi zdravljenja.
All indications:
Vse indikacije
Do not give Ecansya to children and adolescents.
Otrokom in mladostnikom ne dajajte zdravila Ecansya.
Furthermore, Ecansya is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery.
Zdravilo Ecansya se uporablja tudi za preprečevanje novega pojava raka debelega črevesa po kompletni odstranitvi tumorja z operacijo.
9/L should not be treated with capecitabine.
9/l, ne zdravimo s kapecitabinom.
Ecansya tablets should be swallowed whole with water within 30 minutes after a meal.
Tablete zdravila Ecansya je treba pogoltniti cele z vodo v 30 minutah po obroku.
Care should be exercised when capecitabine is co-administered with 2C9 substrates (e.g., phenytoin).
Previdnost je potrebna, kadar kapecitabin dajemo skupaj s substrati 2C9 (npr. fenitoinom).
Creatinine clearance was found to influence the systemic exposure to 5'-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%).
Kreatininski očistek je vplival na sistemsko izpostavljenost 5'-DFUR (35-% povečanje AUC, kreatininski očistek zmanjšan za 50 %) in FBAL (114- % povečanje AUC in padec kreatinskega očistka za 50 %).
Treatment with brivudine can be started 24 hours after the last dose of capecitabine.
Zdravljenje z brivudinom lahko začnemo 24 ur po zadnjem odmerku kapecitabina.
What Ecansya is and what it is used for
Kaj je zdravilo Ecansya in za kaj ga uporabljamo
The AUC0- values in g•h/ml were 7.75, 7.24, 24.6, 2.03 and 36.3.
Vrednosti AUC0-∞ v μg•h/ml so znašale 7,75; 7,24; 24,6; 2,03 in 36,3.
Deficiency of DPD may lead to increased toxicity of capecitabine (see section 4.3 and 4.4).
Pomanjkanje DPD lahko vodi do povečane toksičnosti kapecitabina (glejte poglavji 4.3 in 4.4).
Dehydration should be prevented or corrected at the onset.
Dehidracija: Dehidracijo moramo preprečiti ali popraviti takoj na začetku.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
A. PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
In the event of accidental administration of brivudine to patients being treated with capecitabine, effective measures should be taken to reduce the toxicity of capecitabine.
V primeru nenamernega dajanja brivudina bolnikom, ki se zdravijo s kapecitabinom, je treba uvesti učinkovite ukrepe za zmanjšanje toksičnosti kapecitabina.
See also interaction with coumarin-derivative anticoagulants below, and section 4.4.
Glejte tudi spodnji odstavek o medsebojnem delovanju s kumarinskimi antikoagulanti in poglavje 4.4.
See section 2 "Ecansya contains lactose".
Glejte poglavje 2 "Zdravilo Ecansya vsebuje laktozo".
In a preplanned multivariate Cox analysis, superiority of capecitabine compared with bolus 5-FU/LV was demonstrated.
V vnaprej načrtovani multivariantni Coxovi analizi so dokazali superiornost kapecitabina v primerjavi s 5-FU/LV v obliki bolusa.
For those toxicities considered by the treating physician to be unlikely to become serious or life-threatening, e.g. alopecia, altered taste, nail changes, treatment can be continued at the same dose without reduction or interruption.
Pri toksičnosti, za katero lečeči zdravnik meni, da ne bo postala resnejša ali življenjsko ogrožajoča, kot npr. alopecija, sprememba okusa, spremembe na nohtih, lahko zdravljenje nadaljujemo z enakim odmerkom brez zmanjšanja ali prekinitve.
If the calculated creatinine clearance decreases during treatment to a value below 30 ml/min, Ecansya should be discontinued.
Če se izračunani kreatininski očistek med zdravljenjem zmanjša pod 30 ml/min, je treba zdravljenje z zdravilom Ecansya ukiniti.
- The other ingredients (excipients) are:
- Druge sestavine zdravila (pomožne snovi) so:
Japanese patients had also about 25% lower Cmax and 34% lower AUC for FBAL than Caucasian patients.
Japonski bolniki so imeli v primerjavi s kavkaškimi bolniki prav tako približno 25 % nižjo Cmax in 34 % nižjo AUC za FBAL.
In all clinical trials, patients were instructed to administer capecitabine within 30 minutes after a meal.
V vseh kliničnih preskušanjih so bolniki jemali kapecitabin v 30 minutah po obroku.
5-FU is further catabolised by the enzyme dihydropyrimidine dehydrogenase (DPD) to the much less toxic dihydro-5-fluorouracil (FUH2).
5-FU se nadalje presnovi z encimom dihidropirimidin dehidrogenazo (DPD) v precej manj toksični dihidro-5-fluorouracil (FUH2).
Pharmacotherapeutic group: antineoplastic agents, antimetabolites, ATC code: L01BC06.
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), zaviralci celične presnove (antimetaboliti), oznaka ATC: L01BC06.
At the end of treatment, 37% of patients in the XELIRI and 26% of patients in the FOLFIRI arm were without evidence of the disease (p=0.56).
Na koncu zdravljenja je bilo 37 % bolnikov v skupini s XELIRI in 26 % bolnikov v skupini s FOLFIRI brez znakov bolezni (p = 0,56).
Doses of capecitabine omitted for toxicity are not replaced.
Opuščenih odmerkov kapecitabina zaradi toksičnosti ne nadomeščamo.
Table 9 Key efficacy results for the non-inferiority analysis of Study NO16967 PRIMARY ANALYSIS
Glavni rezultati o učinkovitosti za analizo ne-inferiornosti v študiji NO16967 OSNOVNA ANALIZA
Concomitant use of allopurinol with capecitabine should be avoided.
Sočasnemu jemanju alopurinola in kapecitabina se je treba izogibati.
However this was associated with an increased incidence of gastrointestinal toxicity and neutropenia during first-line treatment with XELIRI (26% and 11% for XELIRI and first line capecitabine respectively).
To pa je bilo povezano s povečano incidenco gastrointestinalnih toksičnosti in nevtropenije med zdravljenjem s shemo XELIRI v prvi liniji (26 % za XELIRI in 11 % za kapecitabin v prvi liniji).
Renal impairment (see section 4.2, 4.4, and 5.2):
Ledvična okvara (glejte poglavja 4.2, 4.4 in 5.2)
It has been reported that the DPYD*2A, c.1679T>G variants lead to a greater reduction in enzymatic activity than the other variants with a higher risk of side effects.
Poročali so, da različici DPYD*2A in c.1679T>G povzročita večje zmanjšanje encimske aktivnosti kot druge različice in predstavljata večje tveganje za neželene učinke.
Ecansya with food and drink You should take Ecansya no later than 30 minutes after meals.
Zdravilo Ecansya skupaj s hrano in pijačo Zdravilo Ecansya morate vzeti najpozneje 30 minut po obroku.
10.4 months
10,4 meseca
Other side-effects seen in this setting are the following:
Drugi neželeni učinki, ki so jih opazili pri tovrstnem zdravljenju, so bili naslednji:
No studies have been conducted to assess the impact of capecitabine on milk production or its presence in human breast milk.
Študije o oceni vpliva kapecitabina na nastajanje mleka ali prisotnosti kapecitabina v materinem mleku pri ljudeh niso bile izvedene.
There is evidence that the metabolism of 5-FU in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, thereby interfering with the synthesis of deoxyribonucleic acid (DNA).
Obstajajo dokazi, da presnova 5-FU v anabolični poti zavira reakcijo metiliranja deoksiuridinske kisline v timidinsko kislino, s čimer ovira sintezo deoksiribonukleinske kisline (DNA).